article thumbnail

CD19 CAR-T agents to boost blood cancer market

European Pharmaceutical Review

It is set to retain its market-leading position as the most lucrative CD19 CAR-T agent in NHL, with annual sales reaching $1.7 Breyanzi sales will also be supplemented by the anticipated approval in chronic lymphocytic leukemia (CLL) in 2027, making it the first and only currently marketed CD19 CAR-T agent to penetrate the CLL market.

article thumbnail

Consequences of the First 10 Drugs Selected for Medicare’s Negotiation Program

PM360

CMS negotiation may lead to additional savings for beneficiaries and for the Medicare program. After this period, CMS will begin to include physician-administered drugs covered under Part B in the program. The IRA sets physician reimbursement of these products at the CMS-established MFP plus 6% versus current average sales price.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

How retailers and “payviders” are disrupting U.S. healthcare in 2024

Clarivate

The downsizing is not a total reversal of Walgreens’ aggressive primary-care clinic expansion plan (which in 2021 imagined 1,000 VillageMD clinics by 2027), but rather a reallocation of capital to increase VillageMD’s density in “high-opportunity” markets—i.e., those with high patient volumes.

Retail 52
article thumbnail

U.S. market access landscape: A push for control is erasing the boundary between payers and providers in U.S. healthcare

Clarivate

CVS then began affiliating with health systems across the country (like Cleveland Clinic ) for physician oversight of MinuteClinic’s staffed midlevel providers, just as Walgreens was rising as a formidable competitor in the convenient care space through its own walk-in clinics that it launched in fall 2006.

article thumbnail

Five points on CMS’s first ten picks for price negotiations

Clarivate

The dearth of cancer drugs (only blood cancer drug Imbruvica made this first list) stems from CMS only pursuing negotiations for Part D drugs in 2026 and 2027, then expanding to Part B drugs in 2028. Part D cannot cover drugs covered under Part A or Part B , forcing them to be addressed separately.

article thumbnail

The Top 10 Clinical Research Companies in the USA

Medico Reach

billion , and by 2027, it is expected to reach around an exciting amount of 115.1 from 2022 to 2027. Moreover, its services are spread through care organizations, hospitals, government agencies, pharmaceutical companies, and physicians. In 2022, the global clinical research market stands at $63.6 billion with a CAGR of 11.0%

article thumbnail

Benefits and Challenges of Telehealth to Consider in Healthcare

Medico Reach

Almost 44% of physicians forecast telehealth use to attend to half of their appointments. As you can observe, 65% of physicians did not use telehealth in the pre-pandemic era. Remote patient monitoring technology leads to effective treatment of lifestyle disorders. Benefits of Telehealth. Enhanced Patient Outcomes.